Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Diphenhydramine + Isatuximab + Methylprednisolone + Ranitidine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Isatuximab||Sarclisa||SAR650984|isatuximab-irfc||CD38 Antibody 17||Sarclisa (isatuximab-irfc) is a humanized monoclonal antibody against CD38 that induces anti-tumor immune reaction against CD38-positive tumor cells (PMID: 24987056). Sarclisa (isatuximab-irfc) in combination with Pomalyst (pomalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received two or more prior therapies, and in combination with Kyprolis (carfilzomib) and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02960555||Phase II||Diphenhydramine + Isatuximab + Methylprednisolone + Ranitidine||Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma||Recruiting||USA||0|